Terry Tate Files for Governor in California

Terry Tate, the former NFL linebacker and star of those hilarious Reebok ads where he runs around clothes lining and tackling people in an office, claims to have filed as a candidate in the California recall election. And he has an appropriately over-the-top press release announcing his candidacy (I especially love the quote at the end),

Once elected, Mr. Tate will tackle white collar crime: “Ya’ll suckah’s who don’t pay taxes and hang out on your Gucci yachts? With Triple T in charge, you know you gonna get caught.” Terry also commits himself to reducing overcrowding at schools, improving air quality, and eliminating “long-[expletive] coffee breaks – five minutes tops, or ya’ll gonna get clocked.”

. . .

Most importantly, a vote for Terry Tate is a vote for a better future for California’s children, families, and businesses: “I’m gonna govern the [expletive] out of this state. Believe that, California.”

It’s a bit tiring to hear all the talking heads say the recall election is turning California into a national joke. No, the enormous deficit already did that. Look, no matter what happens California taxpayers are going to get screwed over to fix California’s deficit. Why not have a little fun along the way?

If I lived in California and actually could get my lazy ass to a voting booth (I usually don’t vote), I’d vote for Arnold Schwarzenegger (especially if he’d use my proposed campaign ad).

What I still can’t get over is just how ripped the guy is at 56. Just 70 years ago, the average life expectancy at birth in the United States was only 59, and here’s this 56-year old looking like he still might be able to go out and win a body building contest (or at least kick the ass of anybody who says he couldn’t).

At the rate things are going, Seth will still be raising money for his marathon charity bike rides well into this 90s, and there will still be flame wars centering on Dave Winer well into the next century.

Mouse and Rat Research Leads to Compound that Might Treat Human Diabetes

Scientists at pharmaceutical company Hoffman-La Roche recently published the results of their research into a compound that boosts production of insulin while simultaneously reducing the release of glucose.

The compound, referred to as RO-28-1675, binds to the glucokinase enzyme. In rats, it boosted glucokinase activity thereby resulting in an increase in insulin production. The compound also increased glucose usage by the liver in both mice and rats, causing glucose levels in the animals to fall.

Hoffman-LaRoche researcher Joseph Grimsby was quoted by Scientific American as saying,

By turning on glucokinase, this novel compound improves insulin secretion by the pancreas and stimulates glucose usage by the liver, both of which are abnormal in diabetes.

If this RO-28-1675 has the same abilities in human beings, an oral version of it could someday replace insulin shots. Human clinical trials of the drug are, however, likely years away.

Source:

Drug shows promise as diabetes pill. Scientific American, July 21, 2003.

Researchers Treat Paralysis in Rats by Using Embryonic Human Stem Cells

Researchers at the University of California at Irvine announced in July that they were able to treat the bruised spines of rats by injecting the animals with human embryonic stem cells.

Dr. Hans Kierstead headed up the research which took human embryonic stem cells and modified them into cells that form the myelin sheath around nerve fibers (oligodendrocytes). The stem cells were then injected into the bruised spinal cords of the rats.

After a little more than two months, the formerly paralyzed rates regained the ability to walk. According to a report on the research in New Scientist,

Analysis of the rats’ spinal cords revealed that the transplanted oligodendrocytes had wrapped themselves around neurons and formed new myelin sheaths. The transplanted cells also secreted growth factors that appear to have stimulated the formation of new neurons.

Kierstead’s team repeated the experiment three times, finding similar results each time.

New Scientist also reports that another team, led by Douglas Kerr at John Hopkins University, also announced in late June that they had performed a similar experiment. Kerr’s team injected undifferentiated human embryonic stem cells into rats with injured spinal cords. The rats regained the ability to support their own weight again 24 weeks after the treatment.

Sources:

Human cells used to make paralyzed rats walk. Charles Arthur, The Independent, July 3, 2003.

Stem cells enable paralyzed rats to walk. New Scientist, July 3, 2003.

Researchers Keep Diabetic Monkeys Alive for 70 Days Using Pancreatic Cells from Pigs

A University of Minnesota researcher presented the results of his successful xenotransplant of islet cells from pigs into monkeys at the American Transplant Congress in June.

In research sponsored by Immerge BioTherapeutics, Dr. Bernhard Hering transplanted pancreatic tissue from pigs into monkeys who were not capable of producing their own insulin. Drugs were used to prevent the monkeys’ immune systems from rejecting the pig cells.

That is not news — cross-species transplanting of islet cells has been performed before. What was new was that as of June the monkeys in Dr. Hering’s experiment had kept producing insulin from the pig islet cells for more than 70 days,

We have been able to reverse diabetes in past islet studies, but we had only seen two or three-week survival times before the graft was lost due to the overwhelming rejection response. The survival times we are reporting on today should only increase as we further optimize the immunosuppressive regimes.

Which, of course, gets us one step closer to the possibility of one day transplanting non-human islet cells into human beings to treat diabetes.

Source:

Pig-to-monkey transplants may herald cure for diabetes. Steve Connor, The Independent (London), June 4, 2003.

PETA Files FTC Complaint Against Iams

In June, People for the Ethical Treatment of Animals filed a complaint with the Federal Trade Commission claming that pet food maker Iams’ has posted on its website a policy related to the use of research animals which PETA claims is false and misleading.

Iams policy reads,

The Iams Company Research Policy

Like humans, our canine and feline companions are faced with many threats to their health. Millions of cats and dogs around the world suffer from allergies, skin and gastrointestinal diseases, kidney failure and painful bone problems.

At The Iams Company, we work hard to advance scientific understanding of how nutrition can help pets resist and recover from such diseases, and how this understanding helps optimize their health so they can lead happier and longer lives. Research plays a key role in accomplishing these goals.

Our research is governed by the following principles.

1. The results must help veterinarians and pet owners worldwide nutritionally enhance the well-being of cats and dogs, and manage important pet health conditions.

2. Studies will only be conducted if alternative, non-animal methods or existing research cannot answer the questions raised.

3. We will ensure the humane treatment of cats and dogs, and provide for animal well-being, socialization and husbandry in a manner compatible with the company’s philosophy, creating a total culture of care. We will also meet or exceed standards established by the Animal Welfare Act of the US, the US Department of Agriculture and Directive 86/609/EEC of the European Union.

4. We will not fund or participate in any study requiring or resulting in the euthanasia of cats or dogs. We will only conduct research that is equivalent to nutritional or medical studies acceptable on people, including: urine, feces, blood and immune cell analysis, allergy tests, and skin and muscle biopsies, for which adequate anesthesia and analgesics will be provided whenever necessary.

5. Research will be closely monitored at internal and external facilities – with the goal being to eliminate even minor pain or discomfort and to create enriched environments for the cats and dogs involved. To enforce this principle, Iams will place, at these facilities, a company-designated and funded person responsible for ensuring the well being of cats and dogs. This trained, qualified person will follow guidelines used at the Paul F. Iams Technical Center to make certain that cats and dogs are properly cared for and socialized.

6. We will test our foods on groups of cats or dogs within the general population who already suffer from target diseases or conditions. However, we will not contract for, nor conduct, any study involving surgeries to create or mimic diseases such as diabetes, stroke, heart disease, kidney disease, or intentional damage to other organs; nor will the company use non-surgical methods to induce or simulate diseases that are not acceptable in nutritional or medical research on humans; nor will the company fund any university positions that may be involved in such activities for the study of cat and dog nutrition.

7. We will not use, in any studies, animals that are already induced with disease or surgically altered through other research; nor will the company conduct such studies under the auspices of any industry association or group.

8. Our findings will be communicated to benefit others who are seeking to improve the health and well-being of cats and dogs, and to help prevent repetition of tests requiring animal involvement.

We are proud that we have led breakthroughs in the health of cats and dogs, and we are committed to continuing this tradition with the principles outlined here as our guide.

In a press release announcing its complaint, PETA claimed that Iams violated its own policy (thereyb misleading consumers) in several areas,

Recently, PETA investigated an Iams contract laboratory and documented horrendous conditions for the animals and cruel practices that it believes show that the company?s claims are deceptive. The claims PETA disputes include the following:

Iams: ?[Iams] will only conduct the veterinary equivalent of any tests on cats or dogs which are acceptable in nutritional or medical studies in people.?
Among PETA?s findings: Tubes were stuck down dogs? throats in order to force them to ingest vegetable oil.

Iams: ?Each animal is given the best possible veterinary care and treated with care and respect.?
Among PETA?s findings: Dogs were dumped together on cold concrete flooring after having huge chunks of muscle cut out of their thighs.

Iams: ?[Iams] will not fund or participate in any study requiring or resulting in the euthanasia of cats or dogs.?
Among PETA?s findings: Twenty-seven of the 60 dogs who had thigh muscle removed were deliberately killed.

Iams: ?We will ensure the humane treatment of cats and dogs ? creating a total culture of care.?
Among PETA?s findings: Cats and dogs had developed neurotic behaviors, including whirling ceaselessly in their cages, from confinement, isolation, and lack of exercise inside barren cages in windowless, dungeon-like buildings. PETA?s investigator witnessed Iams representatives? touring the facility, which was oppressively hot and humid at the time, and failing to take any action to improve the conditions.

Inquiries to the company about PETA’s charges are being met with this reply which outlines Iams responses to PETA’s complaints back in March about an independent contractor that Iams had been using for some animal research,

On March 25, we learned that nutritional studies being conducted for us at an independent facility in the U.S. may have violated our company’s strict
research policy. On March 26, we completed an unannounced visit of the facility to review
procedures and ensure the well-being of dogs and cats at the site.

On March 27, we concluded that the facility did not meet our strict standards regarding air temperature, ventilation, resting beds, and socialization (even though the facility recently passed U.S. government inspections). We made the
decision to end all research at the facility.

In addition, we worked with the facility to relocate Fifi, Maisy, Mickey, and the 16 other dogs to an Iams animal care center. We have an established program for socialization and employee adoption that will give these dogs the
opportunity for a successful transition to a family.

On April 10, we met with PETA to look over the facts and to share our plan for the review of our contract research facilities.

We have now completed comprehensive reviews of all external facilities involved in dog and cat nutritional studies for Iams. This was a major effort which included Iams researchers, P&G veterinarians, non-technical Iams employees who
served as the “eyes and ears” of our consumers, and where possible, independent animal welfare experts.

All of the facilities reviewed comply with government regulations, and the health of the dogs and cats is not at risk. However, we’ve decided to consolidate our nutritional studies at fewer contract facilities, and we will focus more on the implementation of our high standards for dog and cat care.

Also, we are establishing an Independent Animal Care Advisory Board which will be in place and active by July 15. Its role will be to:

1. Actively review external facility compliance with the Iams research policy.

2. Participate in random unannounced inspections of external sites.

3. Critically evaluate our research policy and bring new ideas to enhance animal well being.

4. Evaluate our animal care program to ensure the health and well being of dogs and cats. This evaluation will include site visits to Iams facilities.

Apparently PETA is basing its lawsuit on its belief that Iams has not followed through quickly enough to inspect all of the facilities it uses to conduct animal research. PETA spokesperson Peter Wood told the Cincinnati Post that the complaint was not based on any new information, and in fact Wood casts this as a straightforward animal rights issue. The Post quoted Woods as saying (emphasis added),

Why does PETA have to conduct investigations into what Iams does to get Iams to do what’s right? The tests are inherently cruel. The larger picture is they’re making claims that each animals is treated humanely, which in our opinion is fiction.

If PETA’s position is that any animal research Iams conducts is “inherently cruel” then this is just another frivolous PETA complaint that will do little other than generate a bit of publicity.

Iams, for its part, specifically denies parts of PETA’s claims, including the most sensational part of PETA’s complaint — that almost 30 dogs were killed during testing of food for the company. Iams spokesperson Bryan Brown told the Cincinnati Post,

No dogs involved in Iams studies were killed at that facility. We challenge the accuracy of points made by PETA. We know they have a track record of sensationalism.

Not to mention a track record of inaccuracy and distortion. According to Brown, Iams has already inspected all of the facilities it uses for research. They didn’t find any violations of federal laws or regulations, Brown said, but some did not meet Iams own internal policies and are currently in the process of bringing their procedures into compliance with Iams standards.

Sources:

PETA says Iams CO. Web site makes false statements. Associated Press, June 11, 2003.

Iams: PETA’s charges false. Alexander Coolidge, The Cincinnati Post, June 11, 2003.

Update on Iams Animal Research. Press Release, Iams, April 25, 2003.

PETA Files Complaint With FTC Against Iams Claiming Ads Are False And Misleading. Press Release, People for the Ethical Treatment of Animals, Undated.

The Iams Company Research Policy. Iams, Undated.

African and Dutch Researchers Clone Cow

Africa produced its first cloned animal in April when researchers in South Africa successfully cloned a cow.

The cloned cow was named Futi, which is Zulu for “replica.” Futi was cloned from DNA taken from a cow that holds the African record for milk production at 20 gallons per day.

Researchers at the South AFrican Embryo Plus center and the Danish Agriculture Institute collaborated to clone the animal. The researchers used a zona-free cloning method which has a number of advantages over the method used to initially clone Dolly the sheep, including that zona-free cloning cuts the time involved in half and can be done with simpler equipment and procedures.

Sources:

S. Africa scientists ‘clone cow’. Associated Press, May 7, 2003.

Cow becomes Africa’s first clone. The BBC, May 7, 2003.